Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Debt Ratio (2016 - 2025)

Avalo Therapeutics' Debt Ratio history spans 11 years, with the latest figure at 0.0 for Q2 2025.

  • For Q2 2025, Debt Ratio changed N/A year-over-year to 0.0; the TTM value through Jun 2025 reached 0.0, changed N/A, while the annual FY2024 figure was 0.0, N/A changed from the prior year.
  • Debt Ratio reached 0.0 in Q2 2025 per AVTX's latest filing, up from 0.0 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.58 in Q2 2022 to a low of 0.0 in Q4 2024.
  • Average Debt Ratio over 5 years is 0.27, with a median of 0.35 recorded in 2022.
  • The largest YoY upside for Debt Ratio was 1.26% in 2022 against a maximum downside of 1.26% in 2022.
  • A 5-year view of Debt Ratio shows it stood at 0.41 in 2021, then fell by 1.26% to 0.4 in 2022, then dropped by 28.51% to 0.29 in 2023, then plummeted by 99.17% to 0.0 in 2024, then rose by 22.39% to 0.0 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Debt Ratio are 0.0 (Q2 2025), 0.0 (Q1 2025), and 0.0 (Q4 2024).